Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Nephros, Inc. Q1 2026 Earnings Call - Revenue Hits Record $5.2M Amid Margin Compression and Strategic Expansion
Nephros delivered a milestone first quarter, posting record revenue of $5.2 million and surpassing the $5 million threshold for the first time. The growth was driven by a 23% year-over-year increase i...
- Record Revenue Milestone: Nephros reported first-quarter revenue of $5.2 million, marking the first time the company has surpassed the $5 million quarterly threshold. This performance reflects strong execution across core business lines and expanding adoption of new product applications.
- Programmatic Growth Outpaces Overall Growth: Programmatic revenue grew 23% year-over-year, serving as the primary driver of the company's top-line expansion. This metric underscores the health of the underlying business model, as customers are actively installing, reordering, and expanding usage over time.
- Margin Compression Driven by External Factors: Gross margins fell to 57% from 65% in the prior year quarter. Management attributed the decline to a $200,000 tariff headwind, currency pressures from a strengthening euro, and a strategic shift toward lower-margin commercial applications.
- +7 more takeaways
Ginkgo Bioworks Q1 2026 Earnings Call - Autonomous Lab Strategy Takes Center Stage
Ginkgo Bioworks Q1 2026 earnings call centered on a strategic pivot toward autonomous laboratories, with CEO Jason Kelly outlining plans to scale its Nebula system to over 100 Reconfigurable Automatio...
- Ginkgo Biowinks Q1 2026 revenue was $19 million, down 49% year-over-year, with a $7.5 million non-cash item from the BiomEdit termination excluded from the comparison.
- Cash burn decreased 17% to $48 million in Q1 2026, down from $58 million in Q1 2025, reflecting restructuring efforts and cost discipline.
- The company holds $373 million in cash with zero bank debt, providing a strong balance sheet to fund its autonomous lab strategy.
- +7 more takeaways
PacBio Q1 2026 Earnings Call - Record Consumables Revenue Offsets Vega Funding Headwinds
PacBio reported flat top-line revenue in Q1 2026, but the underlying dynamics tell a sharper story. Consumable revenue hit a record $21.8 million, driven by clinical accounts that grew over 100% year-...
- Total revenue was flat year-over-year at $37.2 million, reflecting a tug-of-war between strong consumable growth and softer instrument demand.
- Consumable revenue reached a record $21.8 million, a 9% increase, with clinical shipments growing over 100% year-over-year.
- Instrument revenue fell 12% to $9.7 million, dragged down by lower average selling prices on the Vega platform and a promotional discount.
- +7 more takeaways
Natural Grocers by Vitamin Cottage Q2 FY2026 Earnings Call - Comps Miss, ERP Upgrade Complete, Guidance Tightens
Natural Grocers delivered a mixed second quarter, with comparable store sales ticking up just 0.5% against a 8.9% surge a year ago. The number tells a story of consumer fatigue. Basket size grew 1.6%,...
- Comparable store sales grew just 0.5%, a sharp deceleration from 8.9% a year ago, signaling consumer fatigue in a value-seeking environment.
- Daily average comps were driven by a 1.6% increase in basket size, while transaction counts declined 1.1%, showing shoppers buying more per trip but visiting less often.
- nPower Rewards membership penetration surged 300 basis points to 84%, proving the loyalty program is the core engine of revenue and a critical buffer against economic uncertainty.
- +9 more takeaways
ICU Medical Q1 2026 Earnings Call - Core Businesses Grow as Tariff Headwinds Offset by Efficiency Gains
ICU Medical delivered a mixed Q1 2026 report where organic growth remained steady despite macroeconomic noise. Revenue came in at $526 million, up 1% organically but down 12% reported due to the decon...
- Total revenue was $526 million, reflecting 1% organic growth but a 12% reported decline due to the deconsolidation of the IV Solutions business into an Otsuka joint venture.
- Adjusted gross margins expanded to 41%, beating expectations, driven by favorable product mix and the exit of lower-margin business segments.
- Adjusted EBITDA held steady at $99 million year-over-year, while adjusted EPS rose 15% to $1.97, supported by cost discipline and mix improvement.
- +7 more takeaways
Xponential Fitness Q1 2026 Earnings Call - Same-Store Sales Dip 6% Amid Digital Ad Shifts, But Management Reaffirms 2026 Guidance and Highlights Retention Strength
Xponential Fitness reported a 6% decline in Q1 2026 same-store studio sales, driven by a tough year-over-year comparison and structural headwinds in digital advertising. Meta’s transition to an AI-dri...
- Same-store studio sales declined 6% overall in Q1 2026, with Club Pilates down 4%, against a tough 9% growth comparison from Q1 2025.
- Member retention improved 36 basis points year-over-year, marking the best retention month since Q1 2024, with Club Pilates 3-year LTV exceeding $2,300.
- Digital advertising headwinds from Meta’s AI-driven Andromeda platform and Google’s AI-generated search results reduced organic traffic and lead flow.
- +7 more takeaways
GSI Technology Q4 FY2026 Earnings Call - SRAM Cash Engine Funds Gemini-II Edge AI Push
GSI Technology closed fiscal 2026 with $25.1 million in revenue, a 22.4% year-over-year jump driven by a resilient SRAM business that now funds its ambitious APU roadmap. The company is pivoting from ...
- Fiscal 2026 revenue reached $25.1 million, up 22.4% year-over-year, anchored by strong demand in the SRAM segment for AI chip development and simulation.
- Gross margins expanded significantly to 54.5% from 49.4% in the prior year, driven by a favorable product mix and increased SRAM sales.
- The company maintains a fortress balance sheet with $67.2 million in cash and no debt, following a $46.9 million registered direct offering in October 2025.
- +9 more takeaways
Caris Life Sciences Q1 2026 Earnings Call - Revenue Surges 79% on ASP Gains and Profitable MCED Preparations
Caris Life Sciences delivered a forceful start to 2026, with Q1 revenue jumping 79% year-over-year to $216 million, driven by an 85% surge in molecular profiling services. The growth story is no longe...
- Total revenue surged 79% year-over-year to $216 million, driven by an 85% increase in molecular profiling services revenue to $211 million.
- Gross margins expanded dramatically to 65% on a GAAP basis, up from 47% in Q1 2025, reflecting strong pricing power and operating leverage.
- Average selling prices (ASP) for tissue tests jumped 70% to over $4,300, while blood test ASPs rose 14% to just under $2,500.
- +7 more takeaways
Blend Labs Q1 2026 Earnings Call - Autopilot AI Agent Drives Strong Growth and Efficiency
Blend Labs delivered a robust start to 2026, beating revenue and profitability expectations while signaling a strategic pivot toward AI-driven operations. Q1 revenue of $30.8 million grew 15% year-ove...
- Q1 2026 revenue reached $30.8 million, beating the high end of guidance, with 15% year-over-year growth driven by both Mortgage Suite and Consumer Banking suites.
- Non-GAAP operating income was $4.1 million above guidance, yielding a 13% operating margin, up 10 points year-over-year, reflecting strong operating leverage.
- Autopilot, Blend’s AI agent, is live in production with 22 lenders, has processed over 7,000 applications, and is already improving cycle times and conversion rates for early adopters.
- +12 more takeaways
Funko Inc Q1 2025 Earnings Call - Record Margins and Strategic Reset Drive Momentum
Funko delivered a surprisingly strong first quarter, defying the usual seasonal doldrums with a 5% sales increase and a record 44% gross margin. The company is executing a deliberate product reset, cu...
- Total sales rose 5% in Q1, with the core collectibles business jumping 17%, signaling strong momentum entering the year.
- Gross margins hit a record 44%, driven by reduced discounting, renewed licensing deals, and improved channel mix.
- Adjusted EBITDA came in at $11 million, significantly beating management expectations and validating the cost-cutting focus.
- +12 more takeaways